Medtronic (MDT) 2024 Wells Fargo Healthcare Conference summary

Industry trends and innovation

• Medtech industry is experiencing strong innovation, especially in areas with large patient needs like diabetes, AFib, and hypertension, leading to healthy growth and pricing power.

• Digital transformation, including AI, data, supercomputing, and robotics, is accelerating across the sector, with increasing integration into products and services.

• Regulatory environment remains supportive of innovation, with the FDA balancing patient safety and competitiveness, expected to continue post-leadership transition.

• AI-based products are being monetized through subscription models and direct charges, with a push to quantify AI's financial impact as more products are commercialized.

• Large cap medtech has underperformed broader markets YTD, but consistent mid-single digit growth and new technology launches are seen as durable drivers.

Market dynamics and geographic focus

• Procedure volumes globally have stabilized at healthy growth rates post-COVID, with only minor impacts from GLP-1s in bariatrics, expected to recover in 2025.

• China remains a high-growth market for procedures despite lower pricing from volume-based pricing policies; localization efforts are being accelerated to mitigate geopolitical risks.

• Pricing has turned slightly positive, attributed to innovation and a focus on new product launches, with over 20% of revenue from products launched in the last three years.

• Risks include geopolitical shifts in China and potential regulatory changes in AI oversight, but opportunities from innovation and healthy procedure volumes outweigh these.

Financial strategy and shareholder value

• Focus is on innovation-driven top-line growth in large, expanding markets, with consistent mid-single digit sales and high single digit EPS growth targeted.

• Operational rigor, digitization, and global capability centers are helping improve margins, with stabilization expected in the back half of the year as inflation and currency pressures ease.

• Capital allocation prioritizes dividends and tuck-in M&A, with a higher bar for acquisitions and a focus on deals closer to commercialization to minimize dilution.

• The company remains open to structural changes if scale benefits in operations, innovation, and customer contracting are not realized.